Medical maggot therapy uses live blowfly larvae to clean wounds; it raises welfare questions about the deliberate killing and use of insects in clinical settings.
Maggot therapy presents a microcosm of the broader invertebrate welfare challenge: we are using large numbers of potentially sentient beings in a medical context with clear benefits and uncertain welfare costs. The welfare question is less urgent than in contexts involving billions of animals but is worth acknowledging as precautionary welfare thinking extends to smaller scales. The primary welfare comparison — medical maggots versus extended antibiotic courses — suggests maggot therapy may represent the lower overall welfare cost option when accounting for antibiotic resistance effects on downstream animal populations.